Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of December 2023. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's issued share capital and voting rights as of November 30, 2023.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital (as of Nov 30, 2023): 4,312,113,405 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 197,068,169 Ordinary Shares.
- Total Voting Rights: 4,115,045,236.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document is a static notification of share capital status rather than a comparative financial report.
Guidance, Outlook, and Risks
The filing text does not provide clear values or commentary regarding guidance, outlook, risks, contingencies, or unusual items. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,115,045,236) against internal holdings to determine if notification thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (197,068,169) to accurately calculate the free float.
- Note that this filing does not contain operational or financial performance data for the period.